Ubrogepant
Ubrogepant is a CGRP receptor blocker taken by mouth to treat a migraine attack, with or without aura, in adults once it has started.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Ubrogepant (Ubrelvy) treats a migraine attack in adults once it starts (it does not prevent them) by blocking the receptor for CGRP, a natural protein involved in migraine; on the market since about 2019, it is a usual next option when triptans (standard migraine drugs) fail or do not suit. It is generally well tolerated; nausea, sleepiness and dry mouth are what people notice most. Stop it and get help for hives, trouble breathing or swelling of the face or throat, and report rising blood pressure or painful, color-changing fingers or toes (Raynaud's phenomenon). Some antibiotics and antifungals are off-limits with it, so have every other medicine checked first.
Clinical pearls
- Grapefruit juice raises ubrogepant levels enough to require a dose change, so mention it if you drink it regularly.
- St. John's Wort, rifampin and seizure medicines like phenytoin can make ubrogepant stop working, so they should be avoided.
- If the migraine lingers, a second dose can follow at least 2 hours after the first, staying under the daily maximum.
- Safety beyond 8 treated migraines in 30 days is not established, so attacks that frequent call for a preventive plan.
Patient information guide A plain-language walkthrough of Ubrogepant, written from its FDA label.
What Ubrogepant is used for
▾
Ubrogepant is used to treat migraine attacks in adults.
- Ubrelvy tablets are for the acute treatment of migraine with or without aura in adults.
- Ubrelvy is not for preventing migraines.
How Ubrogepant works
▾
Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It blocks the receptor for CGRP, a natural protein involved in migraine. Blocking that receptor is how it treats an attack.
Ubrogepant dosage
▾
Ubrelvy tablets are taken by mouth only when you need them for a migraine.
- You can take it with or without food.
- A second dose may be taken at least 2 hours after the first if needed.
- There is a daily maximum, so follow your prescriber and the label.
- Doses may be changed if you have severe liver or kidney problems or take certain other medicines.
Dosing details from the FDA-approved label
From the Ubrogepant prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Acute treatment of migraine (general recommended dosage)
- 50 mg or 100 mg taken orally, as needed, with or without food
- If needed, a second dose may be taken at least 2 hours after the initial dose
- Maximum: 200 mg in a 24-hour period
- The safety of treating more than 8 migraines in a 30-day period has not been established
- Severe Hepatic Impairment (Child-Pugh Class C)
- Initial dose 50 mg
- Second dose (if needed) 50 mg, at least 2 hours after the initial dose
- Severe Renal Impairment (CLcr 15-29 mL/min)
- Initial dose 50 mg
- Second dose (if needed) 50 mg, at least 2 hours after the initial dose
- Concomitant moderate CYP3A4 inhibitors
- Initial dose 50 mg
- Second dose: avoid within 24 hours
- Concomitant weak CYP3A4 inhibitors
- Initial dose 50 mg
- Second dose 50 mg
- Concomitant weak and moderate CYP3A4 inducers
- Initial dose 100 mg
- Second dose 100 mg
- Concomitant BCRP and/or P-gp only inhibitors
- Initial dose 50 mg
- Second dose 50 mg
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION The recommended dose is 50 mg or 100 mg taken orally, as needed. ( 2.1 ) If needed, a second dose may be administered at least 2 hours after the initial dose. ( 2.1 ) The maximum dose in a 24-hour period is 200 mg. ( 2.1 ) Severe Hepatic or Severe Renal Impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose. ( 2.2 , 8.6 , 8.7 ) 2.1 Recommended Dosage The recommended dose of UBRELVY is 50 mg or 100 mg taken orally with or without food. If needed, a second dose may be taken at least 2 hours after the initial dose. The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established. 2.2 Dosage Modification s Dosing modifications for concomitant use of specific drugs and for patients with hepatic or renal impairment are provided in Table 1. Table 1: Dose Modifications for Drug Interactions and for Specific Populations Dosage Modifications Initi a l Dose Second Dose a (if needed) Concomitant Drug [see Drug Interactions ( 7 )] Moderate CYP3A4 Inhibitors ( 7.1 ) 50 mg Avoid within 24 hours Weak CYP3A4 Inhibitors ( 7.1 ) 50 mg 50 mg Strong CYP3A4 Inducers ( 7.2 ) Avoid concomitant use Weak & Moderate CYP3A4 Inducers ( 7.2 ) 100 mg 100 mg BCRP and/or P-gp only Inhibitors ( 7.3 ) 50 mg 50 mg Spec i fic Populations [see Use in Specific Populations ( 8 )] Severe Hepatic Impairment (Child-Pugh Class C) ( 8.6 ) 50 mg 50 mg Severe Renal Impairment (CLcr 15-29 mL/min) ( 8.7 ) 50 mg 50 mg End-Stage Renal Disease (CLcr <15 mL/min) ( 8.7 ) Avoid use a Second dose may be taken at least 2 hours after the initial dose
Read the full Dosage and Administration section on DailyMed →
Ubrogepant side effects
▾
The most common side effects in trials were:
Common side effects
- Nausea
- Sleepiness (somnolence)
- Dry mouth
When to get medical help
- Signs of a serious allergic reaction, such as trouble breathing, or swelling of the face or throat, hives, or rash. Stop the medicine and get help right away. Reactions can happen minutes, hours or days after a dose.
- New or worsening high blood pressure. This was most often reported within 7 days of starting.
- Signs of Raynaud's phenomenon (fingers or toes with pain or color changes). Stop the medicine and contact your healthcare provider.
- Symptoms that do not go away after stopping the medicine should be checked by a healthcare provider.
Ubrogepant warnings and precautions
▾
- Allergic reactions: including anaphylaxis, trouble breathing, swelling of the face or throat, rash, hives and itching. They can occur minutes to days after a dose.
- High blood pressure: new or worsening cases have been reported, most often within 7 days of starting. Some needed treatment or hospitalization.
- Raynaud's phenomenon: new or worsening cases have been reported, some serious. Stop the medicine if symptoms develop.
Ubrogepant interactions
▾
Ubrogepant is broken down mainly by the CYP3A4 enzyme, so drugs that affect it matter.
- Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): must not be used, as they greatly raise ubrogepant levels.
- Moderate and weak CYP3A4 inhibitors (such as fluconazole, verapamil-type effects, grapefruit juice): dose adjustment is needed.
- Strong CYP3A4 inducers (phenytoin, barbiturates, rifampin, St. John's Wort): avoid, because they can make it stop working.
- Moderate or weak inducers: dose adjustment is recommended.
- BCRP or P-gp inhibitors (quinidine, carvedilol, eltrombopag, curcumin): may raise levels and need a dose adjustment.
Interactions listed in the FDA-approved label
From the Ubrogepant prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): Co-administration with ketoconazole resulted in a significant increase in exposure of ubrogepant. UBRELVY should not be used with strong CYP3A4 inhibitors.
- Moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice): Co-administration with verapamil, a moderate CYP3A4 inhibitor, resulted in an increase in ubrogepant exposure. Dose adjustment is recommended: 50 mg initial dose; avoid a second dose within 24 hours.
- Weak CYP3A4 inhibitors: No dedicated drug interaction study was conducted with ubrogepant and weak CYP3A4 inhibitors. Dose adjustment is recommended: 50 mg initial dose and 50 mg second dose if needed.
- Strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John's Wort): Co-administration with rifampin resulted in a significant reduction in ubrogepant exposure; loss of ubrogepant efficacy is expected. Concomitant use should be avoided.
- Moderate or weak CYP3A4 inducers: Co-administration was not evaluated in a clinical study. Dose adjustment is recommended: 100 mg initial dose and 100 mg second dose if needed.
- BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin): May increase the exposure of ubrogepant; clinical interaction studies with inhibitors of these transporters were not conducted. Dose adjustment is recommended: 50 mg initial dose and 50 mg second dose if needed.
Read the label’s full interactions text
7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. ( 2.2 , 7.2 ) For additional dose modifications for moderate or weak CYP3A4 inhibitors and inducers or BCRP and/or P-gp only inhibitors, refer to section 2.2 . ( 7.1 , 7.2 , 7.3 ) 7.1 CYP3A4 I nhibitors Co-administration of UBRELVY with ketoconazole, a strong CYP3A4 inhibitor, resulted in a significant increase in exposure of ubrogepant [see Clinical Pharmacology ( 12.3 ) ] . UBRELVY should not be used with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) [see Contraindication s ( 4 )] . Co-administration of UBRELVY with verapamil, a moderate CYP3A4 inhibitor, resulted in an increase in ubrogepant exposure [see Clinical Pharmacology ( 12.3 ) ] . Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . No dedicated drug interaction study was conducted with ubrogepant and weak CYP3A4 inhibitors. Dose adjustment is recommended with concomitant use of UBRELVY with weak CYP3A4 inhibitors [see Dosage and Administration ( 2.2 )] . 7.2 CYP3A4 I nducers Co-administration of UBRELVY with rifampin, a strong CYP3A4 inducer, resulted in a significant reduction in ubrogepant exposure [ s ee Clinical Pharmacology ( 12.3 ) ] . In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John’s Wort), loss of ubrogepant efficacy is expected, and concomitant use should be avoided. Co-administration of UBRELVY with moderate or weak CYP3A4 inducers was not evaluated in a clinical study. Dose adjustment is recommended with concomitant use of UBRELVY and moderate or weak CYP3A4 inducers [see Dosage and Administration ( 2.2 )] . 7 .3 BCRP and / or P-gp Only Inhibitors Ubrogepant is a substrate of BCRP and P-gp efflux transporters.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Ubrogepant
▾
- Do not use if you have had a serious allergic reaction to ubrogepant or its ingredients.
- Tell your provider about high blood pressure or Raynaud's phenomenon.
- Severe liver or severe kidney impairment calls for a lower dose. Avoid in end-stage kidney disease.
- Pregnancy: animal data suggest possible fetal harm, and there is a pregnancy registry.
- Breastfeeding: ubrogepant passes into breast milk in low amounts.
- Children: safety and effectiveness have not been established.
- Older adults: dosing should be cautious, usually at the low end.
Ubrogepant overdose
▾
The label says that after an overdose, monitoring should continue for at least 24 hours, or longer while symptoms or signs persist. This is because the medicine's half-life is about 5 to 7 hours. Contact poison control or seek medical help if you take too much.
What Ubrogepant does in the body
▾
At twice the maximum recommended daily dose, Ubrelvy did not lengthen the QT interval (a heart rhythm measure) to any clinically relevant extent.
How your body processes Ubrogepant
▾
After you swallow it, ubrogepant peaks in the blood at about 1.5 hours. A high-fat meal delays the peak by about 2 hours and lowers the peak level by 22%, but the total amount absorbed does not change. It is cleared mainly by metabolism through CYP3A4, and most is removed through bile and stool. Its half-life is about 5 to 7 hours.
How to store Ubrogepant
▾
Store between 20°C and 25°C (68°F and 77°F): excursions permitted between 15°C and 30°C (59°F and 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Ubrogepant
144 supplements and herbal products have documented interactions with Ubrogepant in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 3
- Moderate · 103
- Minor · 38
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Ubrogepant: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Ubrogepant — the kind of thing our pharmacy team would talk through with you at the counter.
What is Ubrelvy for?
▾
How do I take it?
▾
What side effects should I expect?
▾
When should I call my doctor?
▾
Can I take it with my other medicines?
▾
Is it safe in pregnancy?
▾
Is Ubrogepant available over the counter?
▾
When was Ubrogepant first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Ubrogepant on HelloPharmacist
Ubrogepant forms and strengths (how it comes)
Ubrogepant is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Ubrogepant inactive ingredients by manufacturer.
Tablet
How this form is used
- Ubrelvy is used for the acute treatment of migraine with or without aura in adults.
- Ubrelvy is not indicated for the preventive treatment of migraine.
- Ubrelvy is taken by mouth as needed, with or without food.
- Ubrelvy: if needed, a second dose may be taken at least 2 hours after the first.
- Ubrelvy: safety of treating more than 8 migraines in a 30-day period has not been established.
Ubrogepant on the U.S. market: products, makers and brands
How Ubrogepant appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 2 Ubrogepant product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2019. Brand names on the directory include Ubrelvy; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (3) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
How widely Ubrogepant is used (Medicaid data)
A general measure of how commonly Ubrogepant is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Ubrogepant is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Ubrogepant prescribed? Of the 1,601 medications we measure, Ubrogepant ranks #312 by Medicaid prescriptions — more than 81% of them.
Utilization by Ubrogepant product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
ubrogepant 100 MG Oral Tablet Most dispensed
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2268221
ubrogepant 50 MG Oral Tablet
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2268229
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Ubrogepant, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 3 of 13 listed Ubrogepant NDCs with Medicaid activity.
Compare Ubrogepant products
A representative set of FDA-listed product records for Ubrogepant — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 50 mg | Oral | Allergan, Inc. | NDA | View NDC → |
| 100 mg | Oral | Allergan, Inc. | NDA | View NDC → |
Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Ubrogepant NDCs →
Ubrogepant side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Ubrogepant — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Ubrogepant in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Ubrogepant FDA approval history
How Ubrogepant went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Ubrogepant recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Ubrogepant recalls since July 2021.
✅No Ubrogepant recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2268216 1 dose form · 2 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 2268220In current FDA listings
Look up RxCUI 2268216 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Ubrogepant supply and shortage status
Whether Ubrogepant is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Ubrogepant costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet · Oral | 50 mg | $108.89 per tablet | NDC details & price history |
| Tablet · Oral | 100 mg | $109.11 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Ubrogepant brand names
Ubrogepant is sold under one brand name in the FDA directory — Ubrelvy. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Ubrogepant: manufacturers and labelers
One company lists Ubrogepant products with the FDA. By number of product records, the largest are Allergan, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Ubrogepant drug class (RxNorm)
Ubrogepant belongs to the Calcitonin Gene-related Peptide Receptor Antagonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Ubrogepant page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Allergan, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →